We apologize! The document was not able to download due to an unknown error. Our team has been notified and we will fix it as soon as possible. Fill out the form below, and we will send you the document as soon as we can!
LACTEL® 75:25 DL-PLGE, IV 0.80-1.20
LACTEL® 75:25 DL-PLGE, IV 0.80-1.20 is an innovative controlled-release excipient with an ester-terminated lactide-glycolide base with a mol ratio of 75:25. With an inherent viscosity of 0.80─1.20 dL/g in HFIP and a degredation period of 6 months, LACTEL® 75:25 DL-PLGE offers excellent stability and performance in controlled drug release applications.
LACTEL® 75:25 DL-PLGE, IV 0.80-1.20 is a functional excipient from Evonik containing a 75:25 mol ratio of D,L-Lactide and Glycolide with a uniform degredation period of 6 months for controlled drug delivery. It is compatible with numerous substance types ranging from peptides and proteins to nanoparticles and microparticles in the formulation of long-acting injectable formulations in veterinary medicine and human generic drug formulations.
Specifications
Physical state: Solid Form: Granules or pellets Color: White to yellowish, off-white to light tan Inherent viscosity (IV) dL/g: 0.80─1.20 (in chloroform) Degradation time: <6 months Density (g/mL): 1.30 Tensile Strength (psi): 6000─8000 Elongation (%): 3─10 Modulus (psi): 2─4x10⁵ CAS No. 26780-50-7
Primary Chemistry: Poly(DL-lactide-co-glycolide)
Features & Benefits
75:25 ratio of D,L-Lactide and Glycolide Ester end group 6-month degradation time Biodegradable Ideal for terminal sterilization Bioabsorbable excipient Suitable for use with small molecules, peptides, proteins, and other substances Non-GMO No added preservatives Cost effective
Applications
Human generic drug formulations Long-acting injectable formulations Price sensitive applications veterinary medicine
ChemPoint will not under any circumstances release personal user information to individuals or companies. All information collection is solely used to support ChemPoint customers service communications. Read our Privacy Notice.
Thank you
Thank you for your inquiry and interest in ChemPoint. We will respond to you shortly.
ChemPoint will not under any circumstances release personal user information to individuals or companies. All information collection is solely used to support ChemPoint customers service communications. Read our Privacy Notice.
Thank you
Thank you for your inquiry and interest in ChemPoint. We will respond to you shortly.
ChemPoint will not under any circumstances release personal user information to individuals or companies. All information collection is solely used to support ChemPoint customers service communications. Read our Privacy Notice.
Document Download
The document currently is provided in the following languages from the supplier at this time.
Document Download
The document currently is provided in the following languages from the supplier at this time.
Are you in the correct region?
We’ve detected that you are located in a different region than the region selected on the website. Would you like to change your region?
Current Region:
English - United States
Hi, let us know if you have any questions as you visit our website.
